医药财经 - 第11页 - 医药门户 - 大连神华机械轻工有限公司

赛诺菲礼来等巨头开打糖尿病药侵权战抢400亿美金市场

2018-10-26 01:58 448 0

也许是真应了那句“药药切克闹”，法国赛诺菲公司（SNY.NYSE，下称“赛诺菲”）和美国礼来制药（NYSE：LLY，下称“礼来”）两家位列全球制药业TOP10的跨国巨头因为一款糖尿病重磅药的专利问题闹上了法庭。7月14日， ...

各治疗领域全球制药企业排名

2018-10-26 01:58 1094 0

全球制药企业排名榜单并不鲜见，每年各大公司年报一经发布，便有研究机构会统计其销售额并进行业绩排名。但如果把各公司销售业绩再拆分，细分不同的治疗领域进行排名，则并不常见。本文我们将为大家介绍抗肿瘤、免疫 ...

Ackman's crusade for Valeant-Allergan combo gets a key nod from proxy advisers

2018-10-26 01:58 554 0

August 5, 2014 | By Carly HelfandBill Ackman hasn't rounded up enough support to call the special meeting of Allergan shareholders that's crucial to Valeant's buyout bid. But now, he's got a proxy adv ...

GSK……还没死

2018-10-26 01:58 1074 0

Note to Big Pharma: Discounts work. GSK price cuts score Advair a payer boostAugust 5, 2014 | By Carly HelfandGlaxoSmithKline giant Advair may be reeling, but it hasn't kicked the bucket yet. And now, ...

诺和诺德比GSK更有市场价值？

2018-10-26 01:58 1046 0

Novo Nordisk more valuable than GlaxoSmithKline? That's what investors say August 5, 2014 | By Tracy StatonWho'd have thought Novo Nordisk ($NVO) could zoom past GlaxoSmithKline ($GSK) in the pharma m ...

全球疫苗产业：80%以上被辉瑞、诺华等巨头垄断

2018-10-26 01:58 564 0

生物制药目前已成为医药产业中的一块“香饽饽”，众多企业投入大量资金研发和生产。疫苗作为生物制药的核心部分，也面临巨大的发展机遇。2010年全球疫苗市场的估值为250亿美元，预计2015~2016年将增长一倍，到2025年 ...

Glenmark to invest $17 million in production facilities in North Carolina

2018-10-26 01:58 1026 0

When India's Glenmark Pharmaceuticals said two weeks ago that it had decided on Union, NC, for its first production operation in North America, it didn't say just how much the company intended to inve ...

因劳资纠纷，辉瑞封锁印度工厂

2018-10-26 01:58 1025 0

刚刚是诺华在新泽西的工厂挂牌出售现在是辉瑞因劳资纠纷，为了抵抗工人暴动，封锁印度工厂。哎…… Labor disputes lead Pfizer to lock workers out of plant in India Pfizer says it has tried, workers s ...

Hospira's Rocky Mount plant meets FDA goals, but one in India does not

2018-10-26 01:58 521 0

Hospira's ($HSP) long troubled Rocky Mount, NC, manufacturing plant is troubled no more. CEO F. Michael Ball says a much anticipated reinspection of the plant by the FDA resulted in no observations. B ...

How big is Novartis' LCZ696 heart drug? Experts bet on a key number

2018-10-26 01:58 1102 0

How big is Novartis' LCZ696 heart drug? Experts bet on a key numberAugust 5, 2014 | By John CarrollIn the pharma business, you're only as good as your next big blockbuster. And in Novartis' ($NVS) cas ...

医药股频现大宗交易疑为股东减持

2018-10-26 01:58 458 0

8月以来，医药股频频现身大宗交易。截至昨日，已有以岭药业、海王生物、长春高新等8只医药股现身大宗交易，3个交易日合计成交金额达3.71亿元。值得注意的是，多只个股的大宗交易怀疑是被股东减持。上述医药股的大宗 ...

康美药业控股股东2010万股被解除质押

2018-10-26 01:58 1060 0

核心提示：康美药业(600518)周二盘后公告称，公司控股股东康美实业有限公司于2014年8月4日将原质押给江西国际信托股份有限公司的公司无限售条件流通股2010万股解除质押，并办理了解除质押登记手续。康美药业(600518) ...

中国医药子公司起诉上海咸池实业

2018-10-26 01:58 554 0

核心提示：中国医药(600056.SH)发布公告称，其下属通用美康医药有限公司(下称“通用美康”)就与上海咸池实业有限公司(下称“咸池实业”)等企业的委托合同纠纷提起诉讼，提出了1.06亿元人民币的赔偿要求。昨晚，中国 ...

科伦药业拟择机在美筹建子公司进军药品市场

2018-10-26 01:58 1134 0

核心提示：科伦药业（002422）5日午间公告，为增强公司研发实力，引进国际先进医药人才资源，进军美国药品市场，公司同意全资子公司科伦国际发展有限公司（简称“科伦国际”）择机在美国筹建全资子公司，总计划投资 ...

Can third to market be a charm for Lilly, Boehringer diabetes med Jardiance?

2018-10-26 01:58 1136 0

Can third to market be a charm for Lilly, Boehringer diabetes med Jardiance?August 6, 2014 | By Carly HelfandJardiance, a diabetes med from Eli Lilly ($LLY) and Boehringer Ingelheim that locked up FDA ...

1 ... 7 8 9 101112 13 14 15 ... 45 / 45 页下一页